DK2391352T3 - Farmaceutiske former til frigivelse af aktive forbindelser - Google Patents

Farmaceutiske former til frigivelse af aktive forbindelser

Info

Publication number
DK2391352T3
DK2391352T3 DK10702287.3T DK10702287T DK2391352T3 DK 2391352 T3 DK2391352 T3 DK 2391352T3 DK 10702287 T DK10702287 T DK 10702287T DK 2391352 T3 DK2391352 T3 DK 2391352T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical form
release
active compounds
pharmaceutical forms
pharmaceutical
Prior art date
Application number
DK10702287.3T
Other languages
English (en)
Inventor
Rodríguez Guillermo Franco
Aduriz Ibón Gutierro
Original Assignee
Laboratorios Farmacéuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmacéuticos Rovi S A filed Critical Laboratorios Farmacéuticos Rovi S A
Application granted granted Critical
Publication of DK2391352T3 publication Critical patent/DK2391352T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10702287.3T 2009-01-30 2010-01-29 Farmaceutiske former til frigivelse af aktive forbindelser DK2391352T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382014A EP2213282A1 (en) 2009-01-30 2009-01-30 Pharmaceutical forms for the release of active compounds
PCT/EP2010/051127 WO2010086425A1 (en) 2009-01-30 2010-01-29 Pharmaceutical forms for the release of active compounds

Publications (1)

Publication Number Publication Date
DK2391352T3 true DK2391352T3 (da) 2018-01-29

Family

ID=40602343

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10702287.3T DK2391352T3 (da) 2009-01-30 2010-01-29 Farmaceutiske former til frigivelse af aktive forbindelser

Country Status (11)

Country Link
EP (2) EP2213282A1 (da)
CY (1) CY1120050T1 (da)
DK (1) DK2391352T3 (da)
ES (1) ES2655689T3 (da)
HR (1) HRP20180103T1 (da)
HU (1) HUE037915T2 (da)
LT (1) LT2391352T (da)
PL (1) PL2391352T3 (da)
PT (1) PT2391352T (da)
SI (1) SI2391352T1 (da)
WO (2) WO2010086427A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120781B (zh) * 2011-03-16 2013-07-17 中国药科大学 一种新型胰岛素口服纳米粒的制备及应用
CN110087298A (zh) 2011-04-01 2019-08-02 三菱电机株式会社 无线通信系统及基站
EP3273239A1 (en) 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482014A (en) 1966-06-29 1969-12-02 Canada Packers Ltd Orally active heparin and method for making and using same
US4703042A (en) 1984-05-21 1987-10-27 Bodor Nicholas S Orally active heparin salts containing multivalent cationic units
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
WO2003094887A1 (en) * 2002-05-09 2003-11-20 Peptron Co., Ltd Sustained release formulation of protein and preparation method thereof
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2222822B1 (es) 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
ATE362395T1 (de) * 2003-10-01 2007-06-15 Debio Rech Pharma Sa Vorrichtung und verfahren zur herstellung von partikeln
US7556826B2 (en) * 2005-01-04 2009-07-07 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070154546A1 (en) 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.

Also Published As

Publication number Publication date
HUE037915T2 (hu) 2018-09-28
EP2213282A1 (en) 2010-08-04
HRP20180103T1 (hr) 2018-04-20
WO2010086425A1 (en) 2010-08-05
EP2391352A1 (en) 2011-12-07
WO2010086427A1 (en) 2010-08-05
PL2391352T3 (pl) 2018-05-30
EP2391352B1 (en) 2017-11-01
SI2391352T1 (en) 2018-04-30
ES2655689T3 (es) 2018-02-21
CY1120050T1 (el) 2018-12-12
PT2391352T (pt) 2018-01-19
LT2391352T (lt) 2018-05-25

Similar Documents

Publication Publication Date Title
ATE515260T1 (de) Stabile nanokapselsysteme für die verabreichung von wirkstoffen
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
HRP20110861T1 (hr) Lijek za liječenje gripe
UA111825C2 (uk) Стабілізований препарат, що містить антитіло проти ngf
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
MX2010014041A (es) Una forma cristalina de posaconazol.
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
WO2010021607A3 (en) Pharmaceutical formulation
WO2010122583A3 (en) Oral pharmaceutical compositions of acid labile substances
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
TN2013000386A1 (en) Suspension type topical formulations comprising cyclic depsipeptide
WO2012092486A3 (en) Modified release benzimidazole formulations
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
DK2391352T3 (da) Farmaceutiske former til frigivelse af aktive forbindelser
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
MX2011006567A (es) Formulaciones de fenilefrina con estabilidad mejorada.
WO2012030308A3 (en) Formulation comprising cellobiose
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.